Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Acute Kidney Injury D058186 34 associated lipids
Acute Lung Injury D055371 33 associated lipids
Mucositis D052016 7 associated lipids
Renal Insufficiency, Chronic D051436 9 associated lipids
Atherosclerosis D050197 85 associated lipids
Jaundice, Obstructive D041781 2 associated lipids
Hyperuricemia D033461 4 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Coronary Stenosis D023921 6 associated lipids
Peanut Hypersensitivity D021183 2 associated lipids
Egg Hypersensitivity D021181 1 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Fetal Weight D020567 12 associated lipids
Stroke D020521 32 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Enterocolitis, Necrotizing D020345 3 associated lipids
Migraine without Aura D020326 1 associated lipids
Amnesia, Anterograde D020324 2 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Venous Thrombosis D020246 11 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Brain Hemorrhage, Traumatic D020201 1 associated lipids
Thrombophilia D019851 6 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Capillary Leak Syndrome D019559 2 associated lipids
Endotoxemia D019446 27 associated lipids
Pancreatitis, Acute Necrotizing D019283 18 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Leukostasis D018921 1 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Leukocyte-Adhesion Deficiency Syndrome D018370 1 associated lipids
Respiratory Syncytial Virus Infections D018357 10 associated lipids
Carcinoma, Embryonal D018236 8 associated lipids
Pelvic Pain D017699 7 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Hypertrophy, Right Ventricular D017380 4 associated lipids
Strongylida Infections D017206 5 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Liver Failure D017093 5 associated lipids
Colitis, Ischemic D017091 3 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Endometrial Neoplasms D016889 30 associated lipids
Malaria, Falciparum D016778 22 associated lipids
Leishmaniasis, Cutaneous D016773 6 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Shukla SD and Hanahan DJ An early transient decrease in phosphatidylinositol 4,5-bisphosphate upon stimulation of rabbit platelets with acetylglycerylether phosphorylcholine (platelet activating factor). 1983 Arch. Biochem. Biophys. pmid:6320731
Wasserman SI Mediators of immediate hypersensitivity. 1983 J. Allergy Clin. Immunol. pmid:6193157
MacIntyre DE and Pollock WK Platelet-activating factor stimulates phosphatidylinositol turnover in human platelets. 1983 Biochem. J. pmid:6411067
O'Flaherty JT et al. 5-L-hydroxy-6,8,11,14-eicosatetraenoate potentiates the human neutrophil degranulating action of platelet-activating factor. 1983 Biochem. Biophys. Res. Commun. pmid:6403011
Stimler NP and O'Flaherty JT Spasmogenic properties of platelet-activating factor: evidence for a direct mechanism in the contractile response of pulmonary tissues. 1983 Am. J. Pathol. pmid:6624879
Hartung HP Acetyl glyceryl ether phosphorylcholine (platelet-activating factor) mediates heightened metabolic activity in macrophages. Studies on PGE, TXB2 and O2- production, spreading, and the influence of calmodulin-inhibitor W-7. 1983 FEBS Lett. pmid:6309563
Swendsen CL et al. 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine: a novel source of arachidonic acid in neutrophils stimulated by the calcium ionophore A23187. 1983 Biochem. Biophys. Res. Commun. pmid:6407484
Bessin P et al. Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs. 1983 Eur. J. Pharmacol. pmid:6687572
Shukla SD et al. Acetylglyceryl ether phosphorylcholine. A potent activator of hepatic phosphoinositide metabolism and glycogenolysis. 1983 J. Biol. Chem. pmid:6309795
Hallam TJ et al. The role of 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (AcGEPC) and palmitoyl-lysophosphatidate in the responses of human blood platelets to collagen and thrombin. 1983 FEBS Lett. pmid:6617886
Roussi J et al. [Success of treatment with a low-molecular-weight heparin fraction in a case of pulmonary embolism complicated by heparin-induced thrombopenia]. 1983 Nouv Rev Fr Hematol pmid:6622253
Valone FH and Goetzl EJ Enhancement of human polymorphonuclear leukocyte adherence by the phospholipid mediator 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphorylcholine (AGEPC). 1983 Am. J. Pathol. pmid:6624880
Barradas MA et al. The effect of fenfluramine on collagen-induced platelet aggregation in vitro. 1983 Br J Clin Pharmacol pmid:6626443
Korth R et al. 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholines: influence on aggregation and [3H]serotonin release of human thrombocytes. 1983 Chem. Phys. Lipids pmid:6627525
Moschidis MC et al. Phosphono-platelet activating factor I. Synthesis of 1-O-hexadecyl-2-O-acetyl-glyceryl-3-(2-trimethyl ammonium-methyl) phosphonate and its platelet activating potency. 1983 Chem. Phys. Lipids pmid:6627527
Patterson R and Harris KE The activity of aerosolized and intracutaneous synthetic platelet activating factor (AGEPC) in rhesus monkeys with IgE-mediated airway responses and normal monkeys. 1983 J. Lab. Clin. Med. pmid:6644157
Nunn B Total and selective desensitisation of human platelets to synthetic platelet activating factor (PAF): evidence that extracellular PAF does not mediate collagen-induced aggregation. 1983 Thromb. Res. pmid:6648898
Myers A et al. Glucocorticoid protection against PAF-acether toxicity in mice. 1983 Br. J. Pharmacol. pmid:6652344
Cervoni P et al. Aortic vascular and atrial responses to (+/-)-1-O-octadecyl-2-acetyl-glyceryl-3-phosphorylcholine. 1983 Br. J. Pharmacol. pmid:6652348
Benveniste J et al. The actions of Paf-acether (platelet-activating factor) on guinea-pig isolated heart preparations. 1983 Br. J. Pharmacol. pmid:6652376
Garcia Gil M and Sanchez Crespo M Dansylcadaverine and rimantadine inhibition of phagocytosis, PAF-acether release, and phosphatidylcholine synthesis in human polymorphonuclear leukocytes. 1983 Immunopharmacology pmid:6654649
Tokumura A et al. Biphasic action of platelet-activating factor on isolated guinea-pig ileum. 1983 Lipids pmid:6656539
Hamasaki Y et al. [Effects of platelet activating factor (PAF:AGEPC) on airway and pulmonary vascular constriction of guinea pigs--with special reference to the relation with TXA2]. 1983 Kokyu To Junkan pmid:6658209
Björk J et al. Paf-acether (platelet-activating factor) increases microvascular permeability and affects endothelium-granulocyte interaction in microvascular beds. 1983 Acta Physiol. Scand. pmid:6659994
Björk J and Smedegård G Acute microvascular effects of PAF-acether, as studied by intravital microscopy. 1983 Eur. J. Pharmacol. pmid:6662199
Yamashita M et al. The metabolism of platelet activating factor in platelets and plasma of various animals. 1983 J Toxicol Sci pmid:6663653
Mueller HW et al. Biosynthesis of platelet activating factor in rabbit polymorphonuclear neutrophils. 1983 J. Biol. Chem. pmid:6406476
Lee TC et al. Stimulation of calcium uptake by 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) in rabbit platelets: possible involvement of the lipoxygenase pathway. 1983 Arch. Biochem. Biophys. pmid:6407399
Billah MM and Johnston JM Identification of phospholipid platelet-activating factor (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in human amniotic fluid and urine. 1983 Biochem. Biophys. Res. Commun. pmid:6407483
Stormorken H et al. A new bleeding disorder: lack of platelet aggregatory response to adrenaline and lack of secondary aggregation to ADP and platelet activating factor (PAF). 1983 Thromb. Res. pmid:6857589
Kloprogge E et al. Stimulus-response coupling in human platelets. Evidence against a role of PAF-acether in the "third pathway'. 1983 Thromb. Res. pmid:6857605
Chilton FH et al. Selective acylation of lyso platelet activating factor by arachidonate in human neutrophils. 1983 J. Biol. Chem. pmid:6408071
Lecrubier C et al. Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin. 1983 Agents Actions pmid:6858789
Gonzalez-Crussi F and Hsueh W Experimental model of ischemic bowel necrosis. The role of platelet-activating factor and endotoxin. 1983 Am. J. Pathol. pmid:6859226
Camussi G et al. Acute lung inflammation induced in the rabbit by local instillation of 1-0-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine or of native platelet-activating factor. 1983 Am. J. Pathol. pmid:6859232
Sánchez-Crespo M et al. Presence in normal human urine of a hypotensive and platelet-activating phospholipid. 1983 Am. J. Physiol. pmid:6859262
Lumb RH et al. Spontaneous and protein-catalyzed transfer of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) between phospholipid bilayers. 1983 Biochim. Biophys. Acta pmid:6860678
Suquet CM and Leid RW Aggregation of equine platelets by PAF (platelet-activating factor). 1983 Inflammation pmid:6862593
Blank ML and Snyder F Improved high-performance liquid chromatographic method for isolation of platelet-activating factor from other phospholipids. 1983 J. Chromatogr. pmid:6863454
Simrock R et al. [Reversible inhibition of thrombocyte stimulation by acetylsalicylic acid and its role in antithrombotic therapy]. 1983 Klin. Wochenschr. pmid:6865264
Hubbard JW et al. Antihypertensive effects of I-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine on plasma renin activity and catecholamine responses in spontaneously hypertensive rats. 1983 Life Sci. pmid:6337313
Acharya SB and MacIntyre DE Platelet products and vascular PGI2 production. 1983 Prostaglandins Leukot Med pmid:6338532
Camussi G et al. Effect of prostacyclin (PGI2) on immune-complex-induced neutropenia. 1983 Immunology pmid:6339375
Billah MM and Lapetina EG Platelet-activating factor stimulates metabolism of phosphoinositides in horse platelets: possible relationship to Ca2+ mobilization during stimulation. 1983 Proc. Natl. Acad. Sci. U.S.A. pmid:6341992
Lapetina EG and Siegel FL Shape change induced in human platelets by platelet-activating factor. Correlation with the formation of phosphatidic acid and phosphorylation of a 40,000-dalton protein. 1983 J. Biol. Chem. pmid:6345519
Camussi G et al. Inhibitory effect of prostacyclin (PGI2) on neutropenia induced by intravenous injection of platelet-activating-factor (PAF) in the rabbit. 1983 Prostaglandins pmid:6346397
Iñarrea P et al. Platelet-activating factor: an effector substance of the vasopermeability changes induced by the infusion of immune aggregates in the mouse. 1983 Immunopharmacology pmid:6347969
Satouchi K [Platelet activating factor (PAF)--a new chemical mediator of inflammation]. 1983 Seikagaku pmid:6350499
McGowan EB and Detwiler TC Characterization of the thrombin-induced desensitization of platelet activation by thrombin. 1983 Thromb. Res. pmid:6356458
Weksler BB Platelets and the inflammatory response. 1983 Clin. Lab. Med. pmid:6360503